Home Medizin Rapid Novor und MAbSilico arbeiten für den weltweit ersten AI-gesteuerten Epitopkartierungsdienst für Antikörper zusammen

Rapid Novor und MAbSilico arbeiten für den weltweit ersten AI-gesteuerten Epitopkartierungsdienst für Antikörper zusammen

von NFI Redaktion

Rapid Novor Inc and MAbSilico have announced a partnership to provide the world’s first AI-guided HDX-MS epitope mapping service for antibody development. By seamlessly integrating experimental data from HDX-MS with predictive analyses derived from AI-driven computer modeling, researchers can gain a comprehensive understanding of the structure, dynamics, and interactions of antibodies with unprecedented precision and speed.

Rapid Novor and MAbSilico partner for world's first AI-Guided epitope mapping service for antibodies
Scientists working on the HDX-MS platform using Waters Cyclic IMS MS technology for advanced antibody epitope mapping analysis. Image Credit: RapidNovor

„Artificial intelligence promises a turning point in the discovery and development of antibody drugs,“ says Iain Rogers, VP Sales and Marketing at Rapid Novor. „By combining the robustness of HDX-MS with the predictive power of AI-driven computer modeling, we have developed a pipeline that can accelerate the discovery and characterization of antibodies.“

The HDX-MS used by Rapid Novor measures the exchange rate of amide hydrogen atoms to deuterium when exposed to deuterium at different time points. By comparing the deuterium levels between bound and unbound states of the antibody-protein complex, the regions protected by antibody binding can be identified. „With our proteomics expertise,“ explains Dr. Dominic Narang, HDX-MS Manager and Lead Research Scientist at Rapid Novor, „We can identify epitopes on target antigens with exceptional resolution down to 1 to 5 amino acids, providing researchers valuable insights into antibody-antigen interactions.“

MAbSilico’s proprietary algorithms are based on data from 1 trillion antibodies and predict binding epitopes on target antigens using 3D structural models and docking-based methods. „Our prediction algorithms are the culmination of 15 years of protein modeling, AI, and machine learning research,“ states Thomas Bourquard, CSO at MAbSilico. „Our computational modeling accurately predicts epitope binding and is always validated by in vitro tests.“ Furthermore, their AI platforms perform epitope binning to screen hundreds of antibody sequences against functionally relevant epitopes and can also assess their development potential.

The integration of AI-guided epitope mapping not only influences the design of in vitro experiments to target the most relevant regions of the antigen, but also ensures the highest quality, reliability, and resolution in identifying binding sites for antibody-antigen interactions. „This AI-integrated approach enables rapid screening of antibodies from extensive candidate pools,“ adds Zak Omahdi, Scientific Business Developer at MAbSilico. „This accelerates the discovery and development of antibodies, ultimately leading to novel therapeutics with improved efficacy.“

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.